# Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB

> **NCT06205589** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections** · enrollment: 1500 (estimated)

## Conditions studied

- Tuberculosis, Pulmonary

## Interventions

- **BIOLOGICAL:** ID93 + GLA-SE vaccine
- **BIOLOGICAL:** Placebo vaccine

## Key facts

- **NCT ID:** NCT06205589
- **Lead sponsor:** Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2028-10-31
- **Final completion:** 2029-10-13
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06205589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06205589, "Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06205589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*